OrthoPediatrics Corp. (KIDS)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 4
Do Nothing: avgDollarVolume20 is $4,707,227.39, below the $5,000,000 liquidity floor required for this strategy.
Company overview
OrthoPediatrics Corp. is a medical technology company focused on developing and commercializing specialized orthopedic implants and devices for children. The company's product line includes solutions for trauma, deformity correction, and spinal deformities like scoliosis. Founded in 2006, OrthoPediatrics serves pediatric orthopedic surgeons and caregivers worldwide.
Fundamental
fairStrong revenue growth and high gross margins, but profitability remains a key challenge.
Strong top-line growth and high gross margins, but still loss-making: FY2025 revenue was $236.3M (about +15% YoY) with ~73% gross margin, yet net margin was about -16.8% and free cash flow was negative. The latest 10-Q shows continued growth and improved operating cash burn, while liquidity remains comfortable (current ratio ~4.8; cash & short-term investments ~$45.9M) and management states it is compliant with debt covenants. Overall: attractive growth profile, but the profitability/FCF turnaround is still the key uncertainty.
Sentiment
goodRecent earnings and guidance raise have been well-received, with supportive analyst commentary.
The near-term narrative is anchored by the Aug-4 Q2 earnings print with a raised FY2026 outlook (announced), and recent coverage is net bullish (last ~14d polarity_score ≈ +0.37) and broadly in-line with the prior 30–90d baseline. Retail/Reddit signal is minimal and the legal/regulatory scan shows no active investigation items (court-case search partially blocked by CAPTCHA), so no red-flag cap applied.
Technical
goodThe stock is in a strong breakout above major averages, but liquidity is below the required threshold.
Trend and momentum are decisively bullish: price is above SMA20/50/200 and EMA9/21, MACD is positive and expanding above its signal, and ADX confirms a strong trend. RSI and Williams %R are overbought, so the move looks extended rather than early-cycle.
You’re looking at 2026-08-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.